![](/images/graphics-bg.png)
Bevacizumab as an Adjunct to Trabeculectomy in Primary Open-Angle Glaucoma: A Randomized Trial
المؤلفون المشاركون
Bilgic, Alper
Sudhalkar, Anand
Trivedi, Megha
Vasavada, Viraj
Vasavada, Vaishali
Vasavada, Shail
Srivastava, Samaresh
Sudhalkar, Aditya
المصدر
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-8، 8ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-01-31
دولة النشر
مصر
عدد الصفحات
8
التخصصات الرئيسية
الملخص EN
Purpose.
To compare the outcomes of trabeculectomy using two different routes of bevacizumab administration as an adjunct in patients with primary open angle glaucoma.
Methods.
Prospective, randomized, masked trial that included 180 eyes of 180 patients of documented primary open angle glaucoma were eligible for surgery.
Patients were randomized to receive either a single intraoperative dose of subconjunctival bevacizumab (1.25 mg, Group I) or topical bevacizumab (5 mg/ml) for 30 days (Group II).
One eye was randomly selected, if both were eligible for surgery.
All patients underwent a complete ocular and systemic examination.
Bleb morphology was examined and scored as per Moorfields system (MBGS) at 1, 3, 6, 12, 18, and 24 months postoperatively.
Visual field, fundus photography, and disc analysis were performed.
Outcome measures (at one year) included (1) comparison of bleb morphology in both groups, (2) proportion of patients achieving surgical success, and (3) side effects of treatment.
Results.
The groups did not differ with respect to age, sex, and crystalline lens status.
Group II patients had significantly lower vascularity scores for central (P=0.042) and peripheral bleb areas (P=0.023) and peripheral nonbleb area (P=0.03).
A significantly larger proportion of Group II (n = 88) patients achieved average vascular scores of less than 2.5 (P=0.0056, Fisher’s test) than Group I (n = 85).
The groups did not differ in terms of surgical success (96% vs.
94%; P=0.54).
No major complications were noted in either group.
Conclusion.
Topical bevacizumab gives a better vascularity profile at one year, but the studied routes appear equally safe and do not seem to affect the outcome in any other way.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Bilgic, Alper& Sudhalkar, Aditya& Sudhalkar, Anand& Trivedi, Megha& Vasavada, Viraj& Vasavada, Shail…[et al.]. 2020. Bevacizumab as an Adjunct to Trabeculectomy in Primary Open-Angle Glaucoma: A Randomized Trial. Journal of Ophthalmology،Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1189747
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Bilgic, Alper…[et al.]. Bevacizumab as an Adjunct to Trabeculectomy in Primary Open-Angle Glaucoma: A Randomized Trial. Journal of Ophthalmology No. 2020 (2020), pp.1-8.
https://search.emarefa.net/detail/BIM-1189747
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Bilgic, Alper& Sudhalkar, Aditya& Sudhalkar, Anand& Trivedi, Megha& Vasavada, Viraj& Vasavada, Shail…[et al.]. Bevacizumab as an Adjunct to Trabeculectomy in Primary Open-Angle Glaucoma: A Randomized Trial. Journal of Ophthalmology. 2020. Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1189747
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1189747
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)